| abstract |
The present invention discloses proteasome inhibitors, FAP-activated prodrugs of proteasome inhibitors, and pharmaceutically acceptable salts of the inhibitors and prodrugs. Related pharmaceutical compositions are also disclosed, and methods of using the inhibitors and prodrugs and compositions thereof, eg, to treat cancer and other cell proliferative diseases. Also disclosed are in vitro and in vivo methods of quantifying FAP expression in biopsies and mammals, respectively. |